Astra will buy EsoBiotec for up to £770m comprised of an initial £327m payment and another £443m in the future if it hits ...

The European Commission approves AstraZeneca's Imfinzi for treating patients with limited-stage small-cell lung cancer based ...

AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for ...

Imfinzi has been approved in the European Union as monotherapy for the treatment of adults with limited-stage small cell ...

The Cambridge-based pharmaceuticals maker has agreed to pay up to USD1 billion for EsoBiotec SA on a cash and debt free basis. This includes an initial payment of USD425 million on deal closing, and ...

Approval based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo ...

The safety profile for Imfinzi was generally manageable and consistent with the known profile of this medicine.

Baidu is not the only Chinese tech company looking to compete with DeepSeek, with Tencent ( 0700.HK) having also recently released a new AI model. Tencent ( 0700.HK) claimed that its Hunyuan Turbo S ...

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that support a wide moat. The strong replenishment of new drugs sets ...

The American Cancer Society awarded its 2025 Medal of Honor to W. Kimryn Rathmell, MD, PhD, renowned kidney cancer expert and ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has been given an average recommendation of “Buy” by the ten ratings firms that are currently covering the company, Marketbeat.com reports. One equities ...